Watchlist Price Alert

Xilio Therapeutics Inc. (XLO)

NASDAQ: XLO · Real-Time Price · USD

0.89

-0.26 (-22.61%)

At close: May 14, 2025, 3:59 PM

0.84

-5.63%

Pre-market: May 15, 2025, 07:34 AM EDT

-22.61% (1D)

Bid	0.83
Market Cap	46.09M
Revenue (ttm)	9.27M
Net Income (ttm)	-41.04M
EPS (ttm)	-1.09
PE Ratio (ttm)	-0.82
Forward PE	-1.69
Analyst	Buy

Ask	0.91
Volume	3,683,068
Avg. Volume (20D)	1,378,011
Open	1.00
Previous Close	1.15
Day's Range	0.84 - 1.07
52-Week Range	0.62 - 1.70
Beta	-0.23

About XLO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XLO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Xilio Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $2.93M misses estimates by $3.82M, with Infinity% YoY growth.

EPS of -0.18 exceeds estimates by 0.12, with 69.49% YoY growth.

Why Price Moved

2 months ago

-6.2%

Xilio Therapeutics shares are trading lower. The c... Unlock content with Pro Subscription

3 months ago

+125.27%

Xilio Therapeutics shares are trading higher after the company announced an option-to-license collaboration agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies.

News

2 months ago · zacks.com

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates

Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.64 per share a year ago.